The Ohio Prep Sports Media Association All-Southwest District high school football teams, selected by a media panel from the ...

Amid Eli Lilly's efforts to strengthen its global manufacturing network, the Indianapolis pharma giant is splashing more than $1 billion into its Indian operations, with plans to tap local partners ...

This article first appeared on GuruFocus. Eli Lilly and Co. (NYSE:LLY) is making a bold long-term bet on India. The U.S. drugmaker plans to pour more than $1 billion into expanding its contract ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it ...

Lilly is also running a head-to-head study comparing its pill to a lower-dose semaglutide pill Eli Lilly & Co.'s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for ...

Lilly Singh, who hosted the NBC’s late night talk series “A Little Late with Lilly Singh,” opened up about the downfall of her show, saying that she believes the production wasn’t set up to succeed.

Shooting 96 episodes in 90 days was never a recipe for success, the YouTube star said on 'The Julia Cunningham Show.' By Etan Vlessing Canada Bureau Chief “I don’t want to say you were set up to fail.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Daniel Payne reports on ...

Eli Lilly and Company has confirmed it’s selling its manufacturing site in Branchburg. The decision was made following a comprehensive assessment, which concluded the Branchburg plant’s capacity will ...

Telangana Chief Minister A. Revanth Reddy inaugurated US pharma major Eli Lilly’s Global Capability Centre (GCC) in Hyderabad on Monday (August 4, 2025). After the launch, the Chief Minister described ...

Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming.